Clinical Trial Update: Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer. [Phase 2]

View source ↗

Summary

Phase II study of letrozole plus erlotinib (Tarceva) in post-menopausal women with ER/PR-positive metastatic breast cancer; the trial was terminated and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• Tarceva (erlotinib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-07-13